ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1871

Identifying Pain Sites Highly Associated with the Fibromyalgia (FM) Phenotype

Louis Lu1, Stephanie Moser2, Chad M. Brummett2 and Daniel J. Clauw3, 1Anesthesiology & Perioperative Care, UC Irvine, Orange, CA, 2Anesthesiology, University of Michigan, Ann Arbor, MI, 3Chronic Pain & Fatigue Research Center, University of Michigan, Ann Arbor, MI

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: fibromyalgia and pain

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Fibromyalgia is challenging to diagnose given its overlapping symptoms with other chronic pain conditions. The most characteristic feature of FM is widespread pain, operationalized by the 2016 FM Survey Criteria as involving at least 4 out of 5 body regions (axial region and limbs). We hypothesized that certain pain locations may be virtually pathognomonic of FM, because these pain sites occur commonly in FM patients but are very uncommon in individuals without FM.

Methods: This is a single center retrospective observational study of patients recruited prior to elective surgery to be in an institutional biorepository. Patients completed the Michigan Body Map to assess the presence or absence of pain in 35 body sites, as well as the 2011 FM Survey Criteria. FM symptom (FS) scores were calculated by adding the widespread pain index (WPI) and symptom severity (SS) scale. Based on the 2016 Modified FM Criteria, patients were diagnosed with FM if they reported pain in 4+ body regions and their FS scores were 12+. Controls were patients that did not meet the criteria. Univariate differences were assessed via t-tests and chi-square tests. Multivariate linear regression accounted for age and gender.

Results: 891 patients (5.5%) out of 16,273 patients were diagnosed with FM. Median age for FM patients was 53 vs 54 (p = 0.62) and 72% female vs 52% (p < 0.0001). Pain sites with the highest odds ratios between FM patients and controls were the left upper arm (23.9), left lower arm (23.4), right upper arm (22.6), right lower arm (21.8), left shoulder (21.6), and right shoulder (18.7). Upon multivariate analysis, statistically significant sites were the head (p = 0.006), face (p = 0.04), left upper arm (p = 0.004), left lower arm (p = 0.0001), left wrist/hand (p = 0.02), left knee (p < 0.0001), left lower leg (p = 0.002), left ankle/foot (p = 0.007), right jaw (p = 0.01), right upper arm (p = 0.006), right elbow (p < 0.0001), right lower arm (p < 0.0001), right wrist/hand (p < 0.0001), right knee (p < 0.0001), and right lower leg (p = 0.001). See Table 1 for the results of all queried body sites.

Conclusion: Pain in non-joint regions of all four limbs, in addition to the head, face and jaw, were all statistically more significantly seen in individuals with FM and unusual in non-FM patients. Though other regions of pain were also commonly seen in FM, because they were also seen in non-FM patients, they would not be helpful in differentiating a chronic pain patient with FM vs. one with a different underlying cause.

Table 1:

Site

FM Patients

Controls

Odds Ratio

Multivariate Analysis p-value

Head

41.6%

8.7%

7.5 (6.5 – 8.7)

0.006

Face

10.2%

2.5%

4.4 (3.4 – 5.6)

0.04

Neck

66.4%

13.8%

12.4 (10.7 – 14.4)

0.08

Upper Back

53.2%

7.4%

14.2 (12.2 – 16.4)

0.79

Abdomen

35.8%

8.9%

5.7 (4.9 – 6.6)

0.53

Lower Back

84.5%

30.0%

12.7 (10.5 – 15.4)

0.10

Pelvis

27.6%

7.3%

4.9 (4.1 – 5.7)

0.80

Left Jaw

20.2%

3.1%

8.0 (6.6 – 9.6)

0.09

Left Shoulder

71.4%

10.3%

21.6 (18.5 – 25.3)

0.47

Left Upper Arm

34.0%

2.1%

23.9 (20.0 – 28.7)

0.004

Left Elbow

31.0%

2.7%

16.0 (13.4 – 19.1)

0.11

Left Lower Arm

29.0%

1.7%

23.4 (19.3 – 28.4)

0.0001

Left Wrist/Hand

59.6%

9.6%

13.9 (12.0 – 16.0)

0.02

Left Buttocks

20.1%

3.1%

8.0 (6.6 – 9.6)

0.58

Left Chest/Breast

16.5%

2.5%

7.6 (6.2 – 9.4)

0.17

Left Hip

66.4%

11.1%

15.8 (13.6 – 18.4)

0.64

Left Groin

15.3%

3.9%

4.5 (3.6 – 5.5)

0.29

Left Upper Leg

40.2%

5.2%

12.2 (10.4 – 14.2)

0.15

Left Knee

59.6%

16.6%

7.4 (6.4 – 8.6)

0.0000

Left Lower Leg

46.7%

5.8%

14.1 (12.2 – 16.4)

0.002

Left Ankle/Foot

57.6%

12.1%

9.8 (8.5 – 11.4)

0.007

Right Jaw

21.8%

3.1%

8.8 (7.3 – 10.6)

0.01

Right Shoulder

70.8%

11.5%

18.7 (16.0 – 21.8)

0.18

Right Upper Arm

33.6%

2.2%

22.6 (18.9 – 27.1)

0.006

Right Elbow

29.9%

3.0%

13.6 (11.4 – 16.2)

0.0000

Right Lower Arm

27.3%

1.7%

21.8 (17.9 – 26.5)

0.0000

Right Wrist/Hand

61.6%

10.0%

14.4 (12.5 – 16.7)

0.0000

Right Buttocks

19.5%

3.1%

7.5 (6.2 – 9.1)

0.77

Right Chest/Breast

16.2%

2.5%

7.5 (6.1 – 9.3)

0.84

Right Hip

64.9%

11.2%

14.6 (12.6 – 17.0)

0.17

Right Groin

16.3%

4.0%

4.6 (3.8 – 5.7)

0.09

Right Upper Leg

41.0%

5.2%

12.5 (10.7 – 14.6)

0.30

Right Knee

61.1%

16.7%

7.8 (6.8 – 9.0)

0.0000

Right Lower Leg

47.0%

5.6%

15.0 (12.9 – 17.5)

0.001

Right Ankle/Foot

57.8%

12.5%

9.6 (8.3 – 11.1)

0.10


Disclosure: L. Lu, None; S. Moser, None; C. M. Brummett, MDHHS (Sub K Michigan OPEN); NIH-DHHS (P90 AR070600-05 CORT) UM MICHIGAN Genomics Initiative, 2,NIDA (ntralized Pain Opiod Non-Responsiveness RO1 DA03826-05); Neuros Medical, Inc. (research funding only), 2,Peripheral Perineural Dexmedetomidine Patent, 7,NIH-DHHS-US (K23 DA038718-04) Chronic Pain through Individualized Opioid Cessation, 2,NIH-DHHS (P50 AR070600-05 CORT), 2,UM Michigan Genomics Initiative, 2,Neuros Medical, Inc. (research funding only), 2; D. J. Clauw, Abbott Pharmaceutical, 5,Aptinyx, 5,Astellas Phamaceutical, 5,Cerephex, 5,Daiichi Sankyo, 5,Pfizer Inc, 5,Pierre Fabre, 8,Samumed, 5,Theravance, 5,Tonix, 5.

To cite this abstract in AMA style:

Lu L, Moser S, Brummett CM, Clauw DJ. Identifying Pain Sites Highly Associated with the Fibromyalgia (FM) Phenotype [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/identifying-pain-sites-highly-associated-with-the-fibromyalgia-fm-phenotype/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identifying-pain-sites-highly-associated-with-the-fibromyalgia-fm-phenotype/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology